

Immune Checkpoint Inhibitors Market 2021 Business Scenario | Key Driving Factors that Will Boost the Growth


PORTLAND, OR, UNITED STATES, October 19, 2021 /EINPresswire.com/ -- Surge in prevalence of cancer across geographies, high demand for ideal therapeutics for cancer treatment, favorable reimbursement policies offered by manufacturers & insurance providers in some countries, and rise in awareness of checkpoint inhibitors for the treatment of cancer due to positive results are the major factors driving the growth of the global immune checkpoint inhibitors market. In addition, surge in geriatric population and increase in technological advancements in screening & diagnosis of cancer supplement the market growth.

However, high cost of treatment associated with immune checkpoint inhibitors is likely to hamper the growth of the industry. Moreover, increased number of pipeline drugs and untapped opportunities in the emerging markets would facilitate future market growth.

Immune Checkpoint Inhibitors Market was valued at \$10.56 billion in 2017 and is projected to reach \$56.53 billion by 2025, registering a CAGR of 20.1% from 2018 to 2025. The report offers an in-depth analysis of the industry by closely monitoring the market trends, key drivers, challenges & opportunities, top investment pockets, key growth strategies, and competitive landscape.

Explore Report Description@ <https://www.alliedmarketresearch.com/immune-check-point-inhibitors-market>

The immune checkpoint inhibitors market has come a long way since the approval of Yervoy, the first immune checkpoint inhibitor, in 2011. However, relatively new entrants, such as Opdivo and Ketruda, have gained popularity over the years due to their high success rates and applicability in late stage cancer treatment. Erstwhile, Opdivo took the lead in terms of revenue, however Keytruda is expected to be the numero uno in the market by end of 2018. In H1-2018, Opdivo



Immune Checkpoint Inhibitors Market



Rise in prevalence of cancer worldwide, increase in demand for ideal therapeutics, positive outcome of checkpoint inhibitors in cancer treatment, favorable reimbursement policies in major countries”

Allied Market Research

had a marginal lead over Keytruda, however the former's shares are expected to dip by the end of 2018. Similarly, Imfinzi, which has a marginal share in the market, will gain share in 2018.

PD-1 inhibitor to capture the highest market share through 2025:-

Among the checkpoint inhibitors types discussed in the study, the PD-1 inhibitor segment captured 82% of the total market share in 2017 and is expected to remain dominant during the study period. The segment would dominate the market through 2025 due to increase in R&D

activities and expected approvals in potential new indications. However, the PD-L1 inhibitor segment would grow at the fastest CAGR of 34.2% through 2025 owing to the increase in adoption of Bavencio & Imfinzi, surge in incidence of cancer, and rise in R&D activities toward atezolizumab, avelumab, & durvalumab. The CTLA-4 inhibitor and others are expected to have steady growth rate during the forecast period.

Lung cancer to hold the largest share, bladder cancer segment to grow rapidly through 2025:-

The report analyzes of the various applications of immune checkpoint inhibitors. The lung cancer segment dominated the global market in 2017 and is expected to continue its dominance through 2025, holding about 45% of the total market share. However, the bladder cancer segment would grow at the fastest CAGR of 21.1% through 2025, owing to the high incidence of bladder cancer and advancements in diagnostic techniques. The report also includes the analysis of melanoma, Hodgkin lymphoma, and other application areas.

North America to be largest revenue contributor, Asia-Pacific to be fastest growing market:-

In 2017, North America contributed around two-thirds share of the global market and is most likely to maintain its lion's share through the forecast period. However, Asia-Pacific would exhibit the fastest CAGR of 22.1% through 2025. Factors such as rapidly changing healthcare infrastructure in developing counties such as India, China, rising prevalence of cancer, increasing awareness of immune checkpoint inhibitors, and growing per healthcare expenditure are expected to drive the market in the Asia-Pacific region. The other regions analyzed in the report are Europe and Latin America, Middle East and Africa (LAMEA).

Key market players:-

The leading companies of the global immune checkpoint inhibitors market include :-

- AstraZeneca PLC.,
- Bristol-Myers Squibb Company,
- Eli Lilly and Company (ARMO Biosciences.),
- Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.),
- F. Hoffmann-La Roche Ltd. (Genentech, Inc.),
- Immutep Limited,
- Merck & Co., Inc.,
- Merck KGaA (EMD Serono, Inc.),
- Novartis AG,
- Pfizer Inc.

For Purchase Enquiry@ <https://www.alliedmarketresearch.com/purchase-enquiry/3723>

Avenue Basic Plan | Library Access | 1 Year Subscription |

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at \$699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Request for 14 days free trial: <https://www.alliedmarketresearch.com/avenue/trial/starter>

"We have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 Over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market."

Trending Reports in Healthcare Industry:

[Rapid Diagnostics Market Global Research By 2030](#)

[Wound Retractor Market Global Research By 2030](#)

[Diabetes Drugs Market Global Research By 2030](#)

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts

David Correa

Allied Analytics LLP

+18007925285 ext.

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/554242770>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.